KR20130104474A - Compositions for preventing or treating pulmonary disease or obesity - Google Patents
Compositions for preventing or treating pulmonary disease or obesity Download PDFInfo
- Publication number
- KR20130104474A KR20130104474A KR1020120025986A KR20120025986A KR20130104474A KR 20130104474 A KR20130104474 A KR 20130104474A KR 1020120025986 A KR1020120025986 A KR 1020120025986A KR 20120025986 A KR20120025986 A KR 20120025986A KR 20130104474 A KR20130104474 A KR 20130104474A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- composition
- obesity
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 208000008589 Obesity Diseases 0.000 title claims abstract description 27
- 235000020824 obesity Nutrition 0.000 title claims abstract description 27
- 208000019693 Lung disease Diseases 0.000 title claims abstract description 16
- 235000000346 sugar Nutrition 0.000 claims abstract description 24
- 206010036790 Productive cough Diseases 0.000 claims abstract description 22
- 208000024794 sputum Diseases 0.000 claims abstract description 21
- 210000003802 sputum Anatomy 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 240000002234 Allium sativum Species 0.000 claims abstract description 14
- 244000068988 Glycine max Species 0.000 claims abstract description 14
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 14
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims abstract description 14
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 14
- 235000004611 garlic Nutrition 0.000 claims abstract description 14
- 235000008397 ginger Nutrition 0.000 claims abstract description 14
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 13
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 239000002075 main ingredient Substances 0.000 claims abstract description 13
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 10
- 235000014443 Pyrus communis Nutrition 0.000 claims abstract description 9
- 244000194101 Ginkgo biloba Species 0.000 claims abstract 3
- 244000088415 Raphanus sativus Species 0.000 claims abstract 3
- 244000273928 Zingiber officinale Species 0.000 claims abstract 3
- 240000001987 Pyrus communis Species 0.000 claims abstract 2
- 235000003805 Musa ABB Group Nutrition 0.000 claims description 14
- 235000015266 Plantago major Nutrition 0.000 claims description 14
- 235000021329 brown rice Nutrition 0.000 claims description 13
- 244000241838 Lycium barbarum Species 0.000 claims description 12
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 241000220324 Pyrus Species 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 10
- 241000283074 Equus asinus Species 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 7
- 240000002045 Guettarda speciosa Species 0.000 claims description 6
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 6
- 240000006079 Schisandra chinensis Species 0.000 claims description 5
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 5
- 230000001629 suppression Effects 0.000 claims description 5
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims description 4
- 235000003097 Artemisia absinthium Nutrition 0.000 claims description 4
- 240000001851 Artemisia dracunculus Species 0.000 claims description 4
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims description 4
- 239000001138 artemisia absinthium Substances 0.000 claims description 4
- 235000021017 pears Nutrition 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- 240000008790 Musa x paradisiaca Species 0.000 claims 2
- 230000037396 body weight Effects 0.000 abstract description 5
- 240000001810 Angelica gigas Species 0.000 abstract description 2
- 235000018865 Angelica gigas Nutrition 0.000 abstract description 2
- 235000017519 Artemisia princeps Nutrition 0.000 abstract 1
- 244000065027 Artemisia princeps Species 0.000 abstract 1
- 244000241872 Lycium chinense Species 0.000 abstract 1
- 240000007594 Oryza sativa Species 0.000 abstract 1
- 235000007164 Oryza sativa Nutrition 0.000 abstract 1
- 241001499733 Plantago asiatica Species 0.000 abstract 1
- 235000009566 rice Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 32
- 241001127637 Plantago Species 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 12
- 241000220259 Raphanus Species 0.000 description 11
- 241000234314 Zingiber Species 0.000 description 11
- 241000218628 Ginkgo Species 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 8
- 240000006891 Artemisia vulgaris Species 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 230000003579 anti-obesity Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960005233 cineole Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 229960003105 metformin Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229930007050 cineol Natural products 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000544270 Angelica acutiloba Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 244000186140 Asperula odorata Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000380130 Ehrharta erecta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- -1 monoginine Chemical compound 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000001162 steatorrhea Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
Description
본 발명은 (a) 쑥, 구기자, 오미자, 마늘, 은행, 엿기름, 무, 메주콩, 현미쌀, 배, 생강, 당귀 및 질경이를 포함하는 주재료, (b) 설탕 및 (c) 물을 포함하는 폐질환 또는 비만의 억제 또는 치료용 조성물에 관한 것이다.
The present invention comprises (a) a main ingredient comprising mugwort, wolfberry, schizandra, garlic, ginkgo, malt, radish, soybean, brown rice, pear, ginger, donkey and plantain, (b) sugar and (c) waste A composition for inhibiting or treating a disease or obesity.
폐는 폐포 세포가 있어서 모세혈관을 통해서 이산화탄소와 산소가 교환된다. 정맥으로부터 심장의 우심방으로 들어온 여러 가지 독성물질을 함유한 피는 폐동맥으로 들어간 후 폐포의 모세혈관을 통해서 산소를 흡수하고, 대신 노폐물을 비롯한 이산화탄소를 내보게 된다. 이렇게 깨끗해진 피가 심장의 좌심방, 좌심실을 거쳐 동맥으로 들어가서 온몸으로 퍼지게 된다. 따라서, 폐포에 유독가스가 유입될 경우 폐질환을 일으킬 뿐 아니라 혈액의 농도 유지에도 영향을 미치게 된다.The lungs have alveolar cells that exchange carbon dioxide and oxygen through capillaries. Blood containing various toxic substances from the vein into the right atrium of the heart enters the pulmonary artery and then absorbs oxygen through the capillaries of the alveoli and instead emits carbon dioxide, including waste products. This cleared blood enters the arteries through the left atrium, the left ventricle, and spreads throughout the body. Therefore, when toxic gas is introduced into the alveoli, not only causes lung disease but also affects the concentration of blood.
즉, 자동차에서 뿜어져 나오는 아황산가스, 대기 중의 먼지, 황사, 담배연기 등은 이러한 메카니즘을 통해서 폐를 병들게 하고 혈액을 산성화하여 질병을 발생시키게 된다.That is, sulfurous acid gas emitted from the car, dust in the air, yellow dust, tobacco smoke, etc., causes the lungs to become sick through this mechanism and acidify the blood to cause disease.
이러한 폐질환 증상 중 하나인 가래를 제거하기 위한 기술로서 대한민국 특허공개공보 제2002-0083782호에는 살구씨, 피마자, 차조기, 박하 및 용뇌 추출물을 유효 성분으로 함을 특징으로 하는 코막힘 해소 및 가래소거용 오일에 대해서 개시되어 있다.
As a technique for removing sputum, one of the symptoms of lung disease, Korean Patent Publication No. 2002-0083782 discloses apricot seed, castor, perilla, peppermint, and sputum elimination, which are characterized by eliminating nasal congestion. A solvent oil is disclosed.
한편, 비만은 여러 가지 요인으로 발병하는 일반적인 질병으로 고지혈증, 지방간, 동맥경화, 심맥질환, 고혈압 또는 당뇨병 등의 여러 가지 합병증을 수반하며, 최근 식생활의 서구화로 인해 심각한 사회적인 문제로 대두되고 있다.On the other hand, obesity is a common disease that is caused by a number of factors, including various complications such as hyperlipidemia, fatty liver, arteriosclerosis, cardiovascular disease, hypertension or diabetes, and has recently emerged as a serious social problem due to westernization of diet.
비만은 현대화에 따라 급격하게 증가하였기 때문에 많은 학자들이 현대화의 병(disease of civilization)이라고 결론을 내리고 있으며(배만종 등, 고려인삼학회지, 14(3):404-415(1990)), 이외에도 당뇨병과 같은 위험한 질환을 유발할 수 있는 잠재적인 요인으로 생각되고 있다. 비만을 감소시켜서 각종 성인병의 발병률을 감소시키기 위한 연구가 지속되고 있는데, 보다 효과적인 비만 해소를 위해서 운동과 함께 식이요법이 연구되었고, 특히 식사요법이 중요한 요인으로 부각되면서 다이어트와 관련된 건강식품 또는 비만치료제에 대한 관심이 높아지고 있다.Because obesity has increased rapidly with modernization, many scholars have concluded that it is the disease of civilization (Bae Jong Jong et al., Journal of the Korean Ginseng Society, 14 (3): 404-415 (1990)). It is thought to be a potential cause of the same dangerous disease. Research has been conducted to reduce the incidence of various adult diseases by reducing obesity. In order to more effectively relieve obesity, dietary therapy was studied along with exercise. There is a growing interest in.
그러나, 현재 비만치료제로서 이용되고 있는 올리스타트(orlistat)는 지방변, 장내가스 발생, 복부팽만감 등의 부작용이 있고, 시부트라민(sibutramine)은 두통, 구갈, 식욕부진, 불면, 변비 등의 부작용이 알려져 있다. 또한, 올리스타트는 비타민 E와 비타민 D의 흡수를 억제하고, 펜터민(phentermine)과 시부트라민은 심박수 증가, 심계항진 또는 현기증을 초래하는 부작용이 있다. However, orlistat, which is currently used as an anti-obesity agent, has side effects such as fatty stool, intestinal gas generation, and bloating. Sibutramine has side effects such as headache, dry mouth, anorexia, insomnia, and constipation. . In addition, orlistat inhibits absorption of vitamin E and vitamin D, and phentermine and sibutramine have side effects that lead to increased heart rate, palpitations, or dizziness.
상기와 같은 비만 문제를 해결하기 위해 종래에 화학 합성 화합물을 이용한 항비만 관련 조성물(그 예로서, 대한민국 공개특허 제1999-0036207호)들이 개발되었으나, 합성 화합물이라는 이유로 일반 소비자에게 거부감뿐만 아니라 복용 시 불쾌감을 주는 경우가 많았다.
In order to solve the problem of obesity, anti-obesity-related compositions (eg, Korean Patent Laid-Open Publication No. 1999-0036207) using a chemical synthetic compound have been developed in the past, but because of the synthetic compound, it is not only rejected by the general consumer when taken Often it was unpleasant.
이에, 본 발명자들은 생약제 등 천연식물을 주재료로 하여 가래 억제 효과를 통한 폐질환 예방 또는 치료 효과를 나타내면서 비만 억제 효과도 나타낼 수 있는 조성물 개발의 필요성을 인식하였다.
Accordingly, the present inventors have recognized the necessity of developing a composition capable of suppressing obesity while showing the effect of preventing or treating lung disease through the effect of suppressing phlegm, using natural plants such as herbal medicines as main ingredients.
본 발명자들은 천연식물을 대상으로 효과적이고 안전한 폐질환 또는 비만의 억제 또는 치료용 조성물을 개발하고자 노력하였다. 그 결과, (a) 쑥, 구기자, 오미자, 마늘, 은행, 엿기름, 무, 메주콩, 현미쌀, 배, 생강, 당귀 및 질경이를 포함하는 주재료, (b) 설탕 및 (c) 물을 포함하는 조성물을 제조한 결과, 우수한 가래 억제 효과 및 비만과 관련된 체중 감소에 우수한 효과를 가짐을 확인함으로써, 본 발명을 완성하였다.The present inventors have tried to develop effective and safe composition for suppressing or treating lung disease or obesity in natural plants. As a result, a composition comprising (a) a main ingredient comprising wormwood, wolfberry, schizandra, garlic, ginkgo, malt, radish, soybean, brown rice, pear, ginger, donkey and plantain, (b) sugar and (c) water As a result of the preparation, the present invention was completed by confirming that it had an excellent effect on suppressing phlegm and weight loss associated with obesity.
따라서, 본 발명의 목적은 폐질환 또는 비만의 억제 또는 치료용 조성물을 제공하는데 있다.
Accordingly, it is an object of the present invention to provide a composition for inhibiting or treating lung disease or obesity.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명 및 청구범위에 의해 보다 명확하게 된다.
Other objects and advantages of the present invention will become apparent from the following detailed description and claims.
본 발명의 일 양태에 따르면, 본 발명은 (a) 쑥, 구기자, 오미자, 마늘, 은행, 엿기름, 무, 메주콩, 현미쌀, 배, 생강, 당귀 및 질경이를 포함하는 주재료, (b) 설탕 및 (c) 물을 포함하고, 상기 (a) 주재료는 쑥 100 중량부에 대하여 구기자 5-15 중량부, 오미자 5-15 중량부, 마늘 1-10 중량부, 은행 1-10 중량부, 엿기름 1-10 중량부, 무 1-10 중량부, 메주콩 1-10 중량부, 현미쌀 1-10 중량부, 배 1-10 중량부, 생강 1-10 중량부, 당귀 1-10 중량부 및 질경이 10-30 중량부를 포함하는 것을 특징으로 하는 폐질환 또는 비만의 억제 또는 치료용 조성물을 제공한다.
According to an aspect of the present invention, the present invention provides a composition comprising (a) mugwort, wolfberry, schizandra, garlic, ginkgo, malt, radish, soybean, brown rice, pear, ginger, donkey and plantain, (b) sugar and (c) water, wherein (a) the main ingredient is 5-15 parts by weight of goji berry, 5-15 parts by weight of Schisandra chinensis, 1-10 parts by weight of garlic, 1-10 parts by weight of ginkgo, malt 1 -10 parts by weight, 1-10 parts by weight of radish, 1-10 parts by weight of soybeans, 1-10 parts by weight of brown rice, 1-10 parts by weight of pears, 1-10 parts by weight of ginger, 1-10 parts by weight of donkey, and plantain 10 It provides a composition for inhibiting or treating lung disease or obesity, comprising -30 parts by weight.
본 발명자들은 천연식물을 대상으로 효과적이고 안전한 폐질환 또는 비만의 억제 또는 치료용 조성물을 개발하고자 노력하였다. 그 결과, (a) 쑥, 구기자, 오미자, 마늘, 은행, 엿기름, 무, 메주콩, 현미쌀, 배, 생강, 당귀 및 질경이를 포함하는 주재료, (b) 설탕 및 (c) 물을 포함하는 조성물을 제조한 결과, 우수한 가래 억제 효과 및 비만과 관련된 체중 감소에 우수한 효과를 가짐을 확인하였다.
The present inventors have tried to develop effective and safe composition for suppressing or treating lung disease or obesity in natural plants. As a result, a composition comprising (a) a main ingredient comprising wormwood, wolfberry, schizandra, garlic, ginkgo, malt, radish, soybean, brown rice, pear, ginger, donkey and plantain, (b) sugar and (c) water As a result of the preparation, it was confirmed to have an excellent effect on suppressing phlegm and weight loss associated with obesity.
본 발명은 (a) 쑥, 구기자, 오미자, 마늘, 은행, 엿기름, 무, 메주콩, 현미쌀, 배, 생강, 당귀 및 질경이를 포함하는 주재료, (b) 설탕 및 (c) 물을 포함한다.The present invention includes (a) main ingredients including mugwort, wolfberry, schizandra, garlic, ginkgo, malt, radish, soybean, brown rice, pear, ginger, donkey and plantain, (b) sugar and (c) water.
본 발명에 이용되는 "쑥"은 국화과에 속하는 다년생 풀로서, 그것은 식용과 약용으로 구분되며, 항균, 혈액응고, 자궁수축, 기관지확장 또는 해열작용 등이 있다고 알려져 있다. 또한, 쑥의 약효 성분은 치네올, 콜린, 유칼리프톨, 아데닌, 모노기닌, 아르테미신 등으로 밝혀져 있으며, 강한 정혈(淨血), 해독, 활혈, 강장, 강정, 소염, 진통, 면역, 이뇨, 지혈, 식욕증진 등의 효과가 있는 것으로 알려져 있으며, 치네올이라는 정유(精油) 성분으로 인해 독특한 향기를 발생시키는데, 이는 몸에 유익한 역할을 하며 살균 및 살충력을 나타낸다고 알려져 있다."Mugweed" used in the present invention is a perennial grass belonging to the Asteraceae, which is divided into edible and medicinal, and is known to have antibacterial, blood coagulation, uterine contraction, bronchial dilatation or antipyretic effect. In addition, the active ingredients of mugwort have been identified as cineol, choline, eucalyptol, adenine, monoginine, artemisine, etc., and strong congestion, detoxification, blood circulation, tonic, gangjeong, anti-inflammatory, analgesic, immunity, diuresis It is known that the effects of hemostasis, appetite, etc., due to the essential oil component (Cineol) generates a unique scent, which is known to play a beneficial role in the body and exhibit sterilization and insecticides.
본 발명에 이용되는 "구기자"는 달걀 모양 또는 긴 타원 모양이고 길이 1.5-2.5 cm인 식물로 7월부터 붉게 익어 7-11월 하순에 수확하고, 종류로는 재래종을 비롯하여 청양종, 일본과 중국에서 들여온 일본1호, 중국1호 등이 있으며, 특징으로는 단백질, 지방, 당질, 칼슘, 인, 철분, 베타인, 루틴, 비타민(A, B1, B2, C) 등이 들어 있어 흡수가 빠르다. 그리고, 강장제, 해열제로 쓰고 간기능 보호 작용이 뛰어나고 부작용이 별로 없는 것으로 알려져 있으며, 시력을 좋게 하고 당뇨병 등의 성인병을 예방하며 폐와 신장의 기능을 좋게 한다고 알려져 있다."Golgija" used in the present invention is an egg-shaped or long oval-shaped plant 1.5-2.5 cm long, ripened red from July, harvested in late July-November, and includes varieties including Cheongyang species, Japan and China. Japan No. 1 and China No. 1 imported from China, and the protein, fat, sugar, calcium, phosphorus, iron, betaine, rutin, vitamins (A, B1, B2, C), etc. . In addition, it is known that it is used as a tonic and antipyretic, and has excellent liver function protection effect and little side effects. It is known to improve vision and prevent adult diseases such as diabetes and improve lung and kidney function.
본 발명에 이용되는 "오미자(Schizandrae Fructus)"는 오미자과의 오미자( Schizandra chinesis BAILL)의 성숙과실을 건조한 것으로, 거담, 진해, 정천, 청혈, 검한, 생진지갈, 보신, 양오장 등의 효능이 있는 것으로 알려져 있다. Schizandrae used in the present invention Fructus ) is a dried fruit of Schizandra chinesis BAILL of Schizandra chinesis BAILL, and is known to have an effect of expectoration, Jinhae, Cheonje, Cheonghyeol, Black, Saengjigal, Bosin and Yangjang.
본 발명에 이용되는 "당귀(Angelica gigantis radix)"는 미나리(Umbelliferae)과에 속한 다년생 초목으로 토당귀(Angelica gigas Nakai, 참당귀)와 일당귀(Angelica acutiloba Kitagawa, 왜당귀) 및 중국당귀(Angelica sinensis)를 일컫는 한약재로, 냉증, 빈혈과 같은 부인과 질환에 주로 쓰이며 혈행을 수월하게 하며 조혈 및 혈류의 개선 효과가 있는 것으로 알려져 있다."Angelica (Angelica used in the present invention gigantis radix ) is a perennial vegetation belonging to the Umbelliferae family, Angelica gigas Nakai , Angelica Angelica and Angelica Angelica acutiloba Kitagawa , Japanese Angelica and Angelica sinensis ) is a Chinese medicine, commonly used for gynecological diseases such as cold and anemia, and is known to have an effect of improving hematopoiesis and blood flow.
본 발명에 이용되는 "질경이(Plantago asiatica)"는 질경이과(Plantaginaceae)에 속하는 다년생 초본으로 우리나라, 중국 및 일본 등의 동아시아와 중앙아시아 등지에 자생하는 약초로 노방초라고 할 만큼 생명력이 강하고 번식력이 우수하다. 꽃이 필 때의 전초를 말린 것을 차전초(車前草), 씨를 차전자(車前子)라 하며 한방에서는 강력한 이뇨제로 신장염, 방광염 및 요도염들에 널리 사용되어 왔으며, 무기질, 단백질, 비타민류 및 다당류 등이 많이 함유되어 있으며, 이들 성분들은 항염증작용에 관여하는 것으로 알려져 있다. Plantago used in the present invention asiatica ) "is a perennial herb belonging to Plantaginaceae . It is a herb that grows in East Asia and Central Asia such as Korea, China, and Japan. Chajeoncho and seeds are called chajeon, and herbal medicine is a powerful diuretic, widely used in nephritis, cystitis and urethritis, and contains a lot of minerals, proteins, vitamins and polysaccharides. They are known to be involved in anti-inflammatory action.
질경이의 주요 생리활성 성분으로 이리도이드 글리코사이드(iridoid glycoside)인 오큐빈(aucubin)과 플란타글루코사이드(plantaglucoside), 각종 스테롤(sterol)류, 아데닌(adenin), 콜린(choline), 점액질(mucilage) 및 각종 지방산이 함유되어 있는 것으로 밝혀져 있으며, 항균작용, 담즙 분비작용, 간독성 방어 작용 및 혈압 강하 작용 등이 보고된 바 있다.
The main bioactive components of plantain are iridoid glycosides, acubin and plantaglucoside, various sterols, adenine, choline and mucilage And it has been found that contains a variety of fatty acids, antibacterial action, bile secretion action, hepatotoxic defense action and blood pressure lowering action has been reported.
바람직한 구현예로서, 본 발명의 조성물에 포함되는 (a) 주재료는 쑥 100 중량부에 대하여 구기자 5-15 중량부, 오미자 5-15 중량부, 마늘 1-10 중량부, 은행 1-10 중량부, 엿기름 1-10 중량부, 무 1-10 중량부, 메주콩 1-10 중량부, 현미쌀 1-10 중량부, 배 1-10 중량부, 생강 1-10 중량부, 당귀 1-10 중량부 및 질경이 10-30 중량부를 포함하고, 보다 바람직하게는 쑥 100 중량부에 대하여 구기자 8-12 중량부, 오미자 8-12 중량부, 마늘 3-7 중량부, 은행 3-7 중량부, 엿기름 3-7 중량부, 무 3-7 중량부, 메주콩 3-7 중량부, 현미쌀 3-7 중량부, 배 3-7 중량부, 생강 3-7 중량부, 당귀 3-7 중량부 및 질경이 15-25 중량부를 포함한다.As a preferred embodiment, the main material (a) included in the composition of the present invention is 5-15 parts by weight of goji berry, 5-15 parts by weight of Schizandra chinensis, 1-10 parts by weight of garlic, 1-10 parts by weight of ginkgo , 1-10 parts by weight of malt, 1-10 parts by weight of radish, 1-10 parts by weight of soybean, 1-10 parts by weight of brown rice, 1-10 parts by weight of pear, 1-10 parts by weight of ginger, 1-10 parts by weight of donkey And it is 10-30 parts by weight of plantain, more preferably 8-12 parts by weight of wolfberry, 8-12 parts by weight of Schisandra chinensis, 3-7 parts by weight of garlic, 3-7 parts by weight of ginkgo, malt 3 -7 parts by weight, 3-7 parts by weight of radish, 3-7 parts by weight of soybeans, 3-7 parts by weight of brown rice, 3-7 parts by weight of pears, 3-7 parts by weight of ginger, 3-7 parts by weight of donkey, and plantain 15 -25 parts by weight.
본 발명의 조성물에 상기 주재료가 상기 함량을 가지는 경우에, 아래 실시예에서 명확히 확인되는 바와 같이, 우수한 가래 억제 효과 및 항비만 효과를 가진다.
When the main material has the above content in the composition of the present invention, as clearly shown in the following examples, it has an excellent sputum inhibiting effect and an anti-obesity effect.
본 발명의 바람직한 구현예에 따르면, 본 발명의 조성물은 (a) 주재료 및 (b) 설탕이 중량비 1 : 1로 포함된다.According to a preferred embodiment of the present invention, the composition of the present invention comprises (a) the main material and (b) sugar in a weight ratio of 1: 1.
본 발명의 다른 바람직한 구현예에 따르면, 본 발명의 조성물은 (a) 주재료 및 (b) 설탕이 (c) 물과 중량비 1 : 4로 포함된다.According to another preferred embodiment of the present invention, the composition of the present invention comprises (a) the main ingredient and (b) sugar in (c) water and weight ratio 1: 4.
본 발명의 조성물에 상기 (a) 주재료 및 (b) 설탕이 (c) 물과 상기 중량비로 포함되는 경우에 우수한 가래 억제 효과 및 항비만 효과를 가진다.When (a) the main material and (b) the sugar are included in the composition of the present invention in (c) water and the weight ratio, it has an excellent sputum inhibiting effect and an anti-obesity effect.
본 발명의 조성물의 제조는 상기 함량으로 주재료, 설탕 및 물을 포함하며, 우선, 상기 주재료를 물로 세척하여 물기를 제거한 다음, 설탕과 상기 전처리한 주재료를 중량비 1 : 1로 혼합하여 주재료를 설탕에 7일 동안 재워서 숙성시킨 다음, 상기 재운 숙성물에 물을 중량비 1 : 4로 혼합하고 100-200℃의 불로 3-5시간 동안 가열하여 제조한다.
The preparation of the composition of the present invention comprises the main material, sugar and water in the above content, first, the main material is washed with water to remove water, and then the sugar and the pretreated main material in a weight ratio of 1: 1 to mix the main material in sugar After aging for 7 days, the mixture is prepared by mixing water at a weight ratio of 1: 4 with the lysed aging product and heating it for 3-5 hours with a fire at 100-200 ° C.
본 발명의 조성물은 폐질환 또는 비만의 억제 또는 치료 효과를 가진다.The composition of the present invention has an inhibitory or therapeutic effect on lung disease or obesity.
본 발명의 바람직한 구현예에 따르면, 상기 폐질환의 억제 또는 치료는 가래 억제이다.According to a preferred embodiment of the invention, the suppression or treatment of the lung disease is sputum suppression.
또한, 본 발명의 조성물은 체중 증가를 억제하고 비만을 개선하는 효과가 높아 비만을 예방 및 개선하는 데에 유용하며, 결국 각종 성인병 및 대사증후군으로 야기된 질환을 개선하는 데에 유효하다.
In addition, the composition of the present invention has a high effect of inhibiting weight gain and improving obesity, and thus is useful for preventing and improving obesity, and is effective for ameliorating diseases caused by various adult diseases and metabolic syndrome.
본 발명의 조성물은 식품 또는 약제학적 조성물로 제조될 수 있다.The composition of the present invention may be prepared as a food or pharmaceutical composition.
본 발명의 조성물이 식품 조성물로 제조되는 경우, 상술한 본 발명의 조성물뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어, 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어, 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물(예를 들어, 레바우디오시드 A, 글리시르히진 등)] 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다.When the composition of the present invention is made of a food composition, it includes not only the composition of the present invention as described above, but also components commonly added in the preparation of food, and include, for example, proteins, carbohydrates, fats, nutrients, seasonings and flavors. Include the first. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol. As the flavoring agent, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.
예컨대, 본 발명의 식품 조성물이 드링크제로 제조되는 경우에는 본 발명의 유효 성분 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액 등을 추가로 포함시킬 수 있다.
For example, when the food composition of the present invention is prepared with a drink, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, tofu extract, jujube extract and the like may be further included in addition to the active ingredient of the present invention.
본 발명의 조성물이 약제학적 조성물로 제조되는 경우, 본 발명의 약제학적 조성물은 약제학적으로 허용되는 담체를 포함한다. 본 발명의 약제학적 조성물에 포함되는 약제학적으로 허용되는 담체는 제제 시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산칼슘, 알기네이트, 젤라틴, 규산칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약제학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. 적합한 약제학적으로 허용되는 담체 및 제제는 Remington's Pharmaceutical Sciences (19th ed., 1995)에 상세히 기재되어 있다.When the composition of the present invention is manufactured from a pharmaceutical composition, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers included in the pharmaceutical compositions of the present invention are those commonly used in the preparation, such as lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, Calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like It doesn't happen. In addition to the above components, the pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like. Suitable pharmaceutically acceptable carriers and agents areRemington's Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약제학적 조성물은 경구 또는 비경구 투여(예컨대, 정맥내 투여, 복강내 투여, 근육내 투여, 피하 투여 또는 국부 투여)할 수 있다.The pharmaceutical compositions of the invention may be oral or parenteral (eg, intravenous, intraperitoneal, intramuscular, subcutaneous or topical).
본 발명의 약제학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. 한편, 본 발명의 약제학적 조성물의 투여량은 바람직하게는 1일 당 100-600 mg/kg(체중)이다.The appropriate dosage of the pharmaceutical composition of the present invention may vary depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate, . On the other hand, the dosage of the pharmaceutical composition of the present invention is preferably 100-600 mg / kg body weight per day.
본 발명의 약제학적 조성물은 당해 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때, 제형은 산제, 과립제, 정제, 캅셀제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 연고, 크림 등의 외용제, 좌제 및 멸균 주사용액 등을 비롯하여 약제학적 제제에 적합한 어떠한 형태로든 사용할 수 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.
The pharmaceutical compositions of the present invention may be prepared in unit dose form by formulating with a pharmaceutically acceptable carrier and / or excipient according to methods which can be easily carried out by those skilled in the art. Or by incorporating into a multi-dose container. In this case, the formulation may be used in any form suitable for pharmaceutical preparations, including powders, granules, tablets, capsules, suspensions, emulsions, syrups, oral formulations such as aerosols, external preparations such as ointments, creams, suppositories, and sterile injectable solutions. It may further include a dispersant or stabilizer.
본 발명의 특징 및 이점을 요약하면 다음과 같다:The features and advantages of the present invention are summarized as follows:
(ⅰ) 본 발명의 조성물은 (a) 쑥, 구기자, 오미자, 마늘, 은행, 엿기름, 무, 메주콩, 현미쌀, 배, 생강, 당귀 및 질경이를 포함하는 주재료, (b) 설탕 및 (c) 물을 포함하고, 상기 (a) 주재료는 쑥 100 중량부에 대하여 구기자 5-15 중량부, 오미자 5-15 중량부, 마늘 1-10 중량부, 은행 1-10 중량부, 엿기름 1-10 중량부, 무 1-10 중량부, 메주콩 1-10 중량부, 현미쌀 1-10 중량부, 배 1-10 중량부, 생강 1-10 중량부, 당귀 1-10 중량부 및 질경이 10-30 중량부를 포함하는 것을 특징으로 하는 폐질환 또는 비만의 억제 또는 치료용 조성물에 관한 것이다.(Iii) The composition of the present invention comprises (a) a main ingredient comprising wormwood, wolfberry, schizandra, garlic, ginkgo, malt, radish, soybean, brown rice, pear, ginger, donkey and plantain, (b) sugar and (c) Water (a) The main material is 5-15 parts by weight of wolfberry, 5-15 parts by weight of Schizandra chinensis, 1-10 parts by weight of garlic, 1-10 parts by weight of ginkgo, 1-10 parts by weight of malt per 100 parts by weight of mugwort 1-10 parts by weight of radish, 1-10 parts by weight of soybeans, 1-10 parts by weight of brown rice, 1-10 parts by weight of pears, 1-10 parts by weight of ginger, 1-10 parts by weight of Angelica, and 10-30 parts by weight of plantain It relates to a composition for inhibiting or treating lung disease or obesity, characterized in that it comprises a part.
(ⅱ) 본 발명의 조성물은 우수한 가래 억제 효과를 가져 폐질환의 예방 또는 치료 효과를 가지며, 체중을 감소시켜 비만으로 야기되는 각종 질환의 예방 및 개선 효과가 있다.(Ii) The composition of the present invention has an excellent effect of inhibiting sputum, has a prophylactic or therapeutic effect of lung disease, and has the effect of preventing and improving various diseases caused by obesity by reducing body weight.
(ⅲ) 또한, 본 발명의 조성물은 천연물질을 유효 성분으로 하여 세포독성 및 피부 부작용이 없어 식품 및 약제학적 조성물에 안전하게 적용할 수 있다.
(Iii) In addition, the composition of the present invention can be safely applied to food and pharmaceutical compositions, since there is no cytotoxicity and skin side effects as a natural substance as an active ingredient.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당 업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.
Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention more specifically, it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples in accordance with the gist of the present invention. .
실시예Example
제조예: 조성물의 제조Preparation Example: Preparation of Composition
상기 표 1의 재료들(실시예 1, 비교예 1 및 2)을 물로 깨끗이 씻은 다음 물기를 제거하였다. 그 다음, 상기 표 1의 재료와 설탕(흑설탕+황설탕)을 중량비 1 : 1로 혼합하여 7일 동안 떡시루 앉히듯 켜켜이 재었다. 그리고, 상기 설탕에 잰 결과물에 물을 중량비 1 : 4로 첨가하고 약한 불(약 150℃)로 4시간 동안 천천히 가열하여 제조하였다. 그리고, 상기 표 1의 라벨링된 성분들을 이용하여 제조된 조성물을 각각 실시예 1, 비교예 1 및 2로 하여 이하 실험에 이용하였다.
The materials of Table 1 (Example 1, Comparative Examples 1 and 2) were washed with water and then drained. Next, the ingredients of Table 1 and sugar (brown sugar + brown sugar) were mixed in a weight ratio of 1: 1, and then weighed on for 7 days. In addition, water was added to the resultant weighed in a weight ratio of 1: 4, and prepared by slowly heating for 4 hours on a weak fire (about 150 ℃). And the compositions prepared using the labeled components of Table 1 were used in the following experiments as Example 1, Comparative Examples 1 and 2, respectively.
실험예Experimental Example 1: 가래 제거 효과 시험 1: sputum removal effect test
약 10년 이상 흡연으로 인한 가래 환자 10명을 대상으로 본 발명 조성물의 가래 제거 효과를 시험하였다. 본 발명의 조성물 500 ml를 시험 대상으로 하여금 하루에 세 번씩 복용시키고 90일 동안 시험을 실시하였다. 그 결과는 아래 표 1에 정리하였다. 가래 제거 효과는 큰 순으로부터 +++, ++, + 및 (-)로 나타내었다. 가래 제거 효과가 나타나지 않는 경우를 (-)로 나타내었다.Sputum removal effect of the composition of the present invention was tested in 10 sputum patients due to smoking for about 10 years or more. 500 ml of the composition of the present invention were administered to test subjects three times a day and tested for 90 days. The results are summarized in Table 1 below. Sputum elimination effects are shown in the order of +++, ++, + and (-) in descending order. The case where the sputum removal effect does not appear is shown as (-).
상기 표 2에서 볼 수 있듯이, 실시예 1의 본 발명의 조성물은 복용 30일 후 가래 제거 효과가 ++로 나타났고, 60일 이후에는 가래 제거 효과가 +++로 나타나 가래 제거 효과가 우수한데 반해, 비교예 1은 복용 90일 후에, 비교예 2는 복용 60일 이후에 가래 제거 효과가 발생하였고, 비교예 1 및 2의 경우 가래 제거 효과가 발생하더라도 실시예 1의 30일째 가래 제거 효과에 비해 약 절반 정도의 효과만 나타내었다.As can be seen in Table 2, the composition of the present invention of Example 1 was found to have a sputum removal effect ++ after 30 days of administration, after 60 days the sputum removal effect is shown as +++ excellent sputum removal effect On the contrary, Comparative Example 1 had a phlegm removal effect after 90 days of administration and Comparative Example 2 had a sputum removal effect after 60 days of administration. Only about half the effect was shown.
가래 제거 효과는 가래 환자의 평소 배출하는 가래 량을 비교하여 평가하였다.
The effect of sputum removal was evaluated by comparing the amount of sputum that is usually released from sputum patients.
실험예Experimental Example 2: 2: 항비만Anti-obesity 효과 시험 Effect test
생후 7주된 ICR 계 수컷 마우스(챨스리버, 일본)를 1주일 동안 예비사육하고 1군 7마리로 비만억제실험에 사용하였다. 동물은 온도 23±1℃, 습도 55±5%, 조명시간 12시간/일(day)로 설정된 항온항실에서 사육하고, 사료에 라보MR(일본농산공업 제조)을 사용하며 물은 자유롭게 섭취할 수 있도록 하였다.Seven-week-old ICR male mice (Higgs River, Japan) were pre-cultured for one week and used in obesity suppression experiments in seven groups of seven. Animals are kept in a constant temperature room set at a temperature of 23 ± 1 ° C, a humidity of 55 ± 5% and an illumination time of 12 hours / day, using Rabo MR (made by Nippon Agricultural Co., Ltd.) for feed, and freely ingesting water. It was made.
상기 실시예 1, 비교예 1 및 2를 시료로 하여, 2주간 100 mg/kg의 농도로 상기 마우스에 경구 투여한 다음 투여 2주 후 체중의 변화를 측정하고 그 결과는 아래 표 3에 정리하였다. 마우스는 투여하기 전날부터 절식(絶食) 상태로 하여 다음 날 강제로 단회(單回) 투여하였다. 그리고, 현재 비만치료제로 이용되고 있는 메트포르민(metformin)(농도: 100 mg/kg)을 양성 대조군으로 이용하였다.Example 1, Comparative Examples 1 and 2 as a sample, the oral administration to the mouse at a concentration of 100 mg / kg for 2 weeks and then measured the change in body weight 2 weeks after administration and the results are summarized in Table 3 below . The mice were fasted from the day prior to administration and were forced to the next day. In addition, metformin (concentration: 100 mg / kg), which is currently used as an obesity agent, was used as a positive control.
(양성대조군)Metformin
(Positive control)
상기 표 3에 기재된 바와 같이, 실시예 1은 비교예 1, 2 및 메트포르민 투여군(양성대조군)에 비해서 비만억제 효과가 우수하였고, 특히 현재 비만치료제로 이용되고 있는 메트포르민보다도 체중 증가율이 감소하였음을 알 수 있다.
As shown in Table 3, Example 1 was superior to the comparative examples 1, 2 and metformin-administered group (positive control group), the effect of inhibiting obesity, in particular, it was found that the weight gain rate is reduced than metformin currently used as an obesity treatment agent Can be.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당 업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
Claims (5)
(a) a main ingredient comprising wormwood, wolfberry, schizandra, garlic, ginkgo, malt, radish, soybean, brown rice, pear, ginger, donkey and plantain, (b) sugar and (c) water, and (a) ) The main ingredients are 5-15 parts by weight of goji berry, 5-15 parts by weight of Schisandra chinensis, 5-15 parts by weight of Schisandra chinensis, 1-10 parts by weight of garlic, 1-10 parts by weight of ginkgo, 1-10 parts by weight of malt, 1-10 parts by weight of radish. , 1-10 parts by weight of soybeans, 1-10 parts by weight of brown rice, 1-10 parts by weight of pears, 1-10 parts by weight of ginger, 1-10 parts by weight of Angelica, and 10-30 parts by weight of plantain Composition for inhibiting or treating disease or obesity.
The composition of claim 1, wherein the composition comprises (a) the main material and (b) sugar in a weight ratio of 1: 1.
2. The composition of claim 1, wherein (a) the main material and (b) sugar comprise (c) water and a weight ratio of 1: 4.
The composition of claim 1, wherein the suppression or treatment of lung disease is sputum suppression.
The composition of claim 1, wherein the composition is a food composition or a pharmaceutical composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120025986A KR101347807B1 (en) | 2012-03-14 | 2012-03-14 | Compositions for Preventing or Treating Pulmonary Disease or Obesity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120025986A KR101347807B1 (en) | 2012-03-14 | 2012-03-14 | Compositions for Preventing or Treating Pulmonary Disease or Obesity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130104474A true KR20130104474A (en) | 2013-09-25 |
| KR101347807B1 KR101347807B1 (en) | 2014-01-03 |
Family
ID=49453308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120025986A KR101347807B1 (en) | 2012-03-14 | 2012-03-14 | Compositions for Preventing or Treating Pulmonary Disease or Obesity |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101347807B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3011179A1 (en) * | 2013-10-01 | 2015-04-03 | Rocher Yves Biolog Vegetale | USE OF AN ARTEMISIA ORIENTALIS EXTRACT IN A SLIMMING COSMETIC COMPOSITION |
| CN104645174A (en) * | 2015-03-04 | 2015-05-27 | 姒建华 | Lung-clearing absorbent |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020060671A (en) * | 2002-07-02 | 2002-07-18 | 이혜복 | A composition for preventing a disease in the lung, a method for producing the composition and a method for using the composition |
| KR20030005086A (en) | 2002-11-08 | 2003-01-15 | 주식회사 이롬라이프 | Diet composition containing freeze-dried uncooked food and dietary fiber |
| KR100728055B1 (en) * | 2005-02-24 | 2007-06-13 | (주)바이오뉴트리젠 | food for preventing fatness and hyperlipemia |
| KR100865513B1 (en) | 2007-03-15 | 2008-10-29 | 강화군 | Composition for preventing and treating obesity comprising the alcoholic extract of gang-hwa mugwort |
-
2012
- 2012-03-14 KR KR1020120025986A patent/KR101347807B1/en not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3011179A1 (en) * | 2013-10-01 | 2015-04-03 | Rocher Yves Biolog Vegetale | USE OF AN ARTEMISIA ORIENTALIS EXTRACT IN A SLIMMING COSMETIC COMPOSITION |
| CN104645174A (en) * | 2015-03-04 | 2015-05-27 | 姒建华 | Lung-clearing absorbent |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101347807B1 (en) | 2014-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101229254B1 (en) | Composition for immune enhancement comprising the extract of Young antler, Ligusticum acutilobum, Cornus officinalis, Chinese matrimony vine, Curcuma aromatica Salisb, Yam, Aurantii nobilis pericarpium, Agastache rugosa, Gastrodia elata blume, Cinnamomum loureirii, Schizandra chinensis, Ginseng steamed red, snake's beard and citrus powder, as active ingredient | |
| KR100913243B1 (en) | A drink composition for eliminating hangover | |
| KR101346244B1 (en) | Composition for preventing or relieving alcohol-induced hangover comprising medicinal herbs | |
| KR20060020923A (en) | Functional food compositions having the effect on eliminating an alcoholic hangover and improvement of liver function | |
| KR20090078662A (en) | Calcium compound containing natural product composition for curing a hangover and preparation method thereof | |
| WO2023125798A1 (en) | Traditional chinese medicine composition and preparation method and application thereof | |
| KR100771524B1 (en) | Composition for improving liver function comprising herbal mixture extract | |
| KR101930277B1 (en) | Composition for Preventing and Improving Hangover | |
| CN104208393B (en) | It is a kind of to be used to prevent Chinese medicine composition of infectious bronchitis of chicken and preparation method thereof | |
| KR101474125B1 (en) | Composition comprising complex extract of Astragalus membranaceus BUNGE, Saposhnikovia divaricata Schiskin, Ostericum koreanum Maximowicz, Scutellaria baicalensis Georgi and Atractylodes japonica Koidz for preventing or treating asthma, bronchitis or pneumonia | |
| KR20110075593A (en) | Antibiotic functional food containing extract of platycodon grandiflorum and garlic for preventing and improving respiratory organ disease | |
| KR101347807B1 (en) | Compositions for Preventing or Treating Pulmonary Disease or Obesity | |
| KR20070101443A (en) | Composition for removing hangover comprising herbal mixture extract | |
| CN109464540B (en) | Spray for relieving discomfort of oral cavity and throat and preparation method thereof | |
| CN108523121A (en) | A kind of functional food and preparation method thereof of anti-haze clearing lung-heat | |
| KR100815277B1 (en) | Antihyperlipidemia Agent Comprising Red Ginseng Acid Polysaccharide and Lycium Chinense Extract | |
| KR102282839B1 (en) | Composition for relieving or improving hangover | |
| KR20140041024A (en) | Compositions for preventing or treating obesity comprising of allium hookeri extract as an ingredient | |
| KR101479096B1 (en) | Health functional food comprising extracts of herbal mixture for preventing or improving edema of delivered or pregnant woman | |
| CN107669795B (en) | Composition for relieving chemical liver injury caused by alcohol | |
| KR101935861B1 (en) | Functional food composition for removing hangover and improving liver function and manufacturing method for thereof | |
| KR101332801B1 (en) | Compositions for Preventing or Treating Obesity | |
| KR102439636B1 (en) | Composition for alleviating muscle tics and depression and manufacturing method thereof | |
| KR100495825B1 (en) | A composition of neutraceutical food for improving liver functions and treating hepatic diseases, and preparing method thereof | |
| CN109820826B (en) | Anti-inflammatory traditional Chinese medicine granules and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20161227 Year of fee payment: 4 |
|
| LAPS | Lapse due to unpaid annual fee |